

Claims

- [Claim 1] A method for treating or preventing vasomotor symptoms in a subject in need thereof, the method comprising:
administering to the subject
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof at a daily dose of 10 mg or less.
- [Claim 2] The method according to claim 1 wherein the daily dose is within the range of 1 mg to 10 mg.
- [Claim 3] The method according to claim 1 or 2 wherein the daily dose is within the range of 5 mg to 10 mg.
- [Claim 4] The method according to claim 1 or 2 wherein the daily dose is within the range of 1 mg to 5 mg.
- [Claim 5] The method according to any one of claims 1 - 3 wherein the daily dose is 10 mg.
- [Claim 6] The method according to any one of claims 1 - 4 wherein the daily dose is 5 mg.
- [Claim 7] The method according to any one of claims 1, 2 and 4 wherein the daily dose is 1 mg.
- [Claim 8] The method of any one of claims 1 - 7, wherein the subject is a human subject.
- [Claim 9] The method of claim 8, wherein the human subject is a menopausal woman.
- [Claim 10] The method of claim 8, wherein the human subject is a perimenopausal woman.
- [Claim 11] The method of claim 8, wherein the human subject is a postmenopausal woman.
- [Claim 12] The method of claim 8, wherein the human subject is a cancer patient.
- [Claim 13] The method of claim 8, wherein the human subject is undergoing or has undergone treatment for cancer.
- [Claim 14] The method of claim 13, wherein the treatment for cancer is gonadal ablative therapy or gonadal hormonal suppressive therapies.
- [Claim 15] The method of claim 8, wherein the human subject has undergone surgery.
- [Claim 16] The method of claim 15, wherein the surgery is hysterectomy, oophorectomy, or orchiectomy.
- [Claim 17] The method of any one of claims 1 - 16, wherein the vasomotor

- symptoms are hot flashes.
- [Claim 18] The method of any one of claims 1 - 16, wherein the vasomotor symptoms are night sweats.
- [Claim 19] The method of any one of claims 1 - 18, wherein
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered immediately upon sensing the onset of a vasomotor symptom.
- [Claim 20] The method of any one of claims 1 - 19, wherein
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered daily.
- [Claim 21] The method of any one of claims 1 - 19, wherein
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered once daily.
- [Claim 22] The method of any one of claims 1 - 19, wherein
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered twice daily.
- [Claim 23] The method of any one of claims 1 - 22, wherein a lower dose of
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered with an additional active agent.
- [Claim 24] The method of any one of claims 1 - 23, wherein
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof is administered as a composition comprising
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- [Claim 25] The method of claim 24, wherein the composition is a pharmaceutical composition.
- [Claim 26] A pharmaceutical composition comprising
4-((1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino)sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof at a lower dose of 10 mg or less and a pharmaceutically acceptable carrier for treating or preventing vasomotor symptoms in a

- subject in need thereof.
- [Claim 27] The pharmaceutical composition of claim 26, further comprising an additional active agent.
- [Claim 28] Use of
4-({(1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino
}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof or
a composition comprising the same as an active ingredient for treating
or preventing vasomotor symptoms in a subject in need thereof.